


- Total HIV/AIDS cases 1985-2017: **22980**
- People living with HIV/AIDS (PLWHA): **15009**
- New HIV/AIDS cases in 2017: **692**
- Patients on cART/post-exposure prophylaxis: **12247**

< 1 year	6
1-14 years	190
15-19 years	171
20-29 years	6537
30-34 years	2103
35-39 years	1523
40-49 years	2400
50-59 years	1218
≥ 60 years	861




Current challenges in the Pediatric Cohort

- Jul. 1989- Dec. 1990:
 - **1090 pediatric AIDS cases identified**
 - **97% <3 years;**
 - 62% living in institutions
- The **largest 27-30 year-old cohort in Europe**
- An estimated **10,000 children infected**
- Sex-ratio 1:1
- **F1 subtype** almost 100 %
- Long-term survivors (**~6000**)
- **Multiple ART regimens (10-15!)**
 - Salvage tx
 - ARV toxicities
 - “Therapeutic exhaustion”
- Have/ want to have children of their own:
 - Vertical transmission problems↓
 - Teratogenicity of long-term use of ART

MTCT Demographic changes

- Most MTCT cases occur in mothers with a recent HIV diagnosis as a result of intravenous drug use or sexual transmission.




- High national ART coverage in mothers (95%) and infants (99%)
- Avoidance of breastfeeding is achieved in 90% of cases (studies)
- Caesarean sections remains the measure with the lowest uptake (between 60-80% in various studies)

Intravenous drug users – high incidence, co-morbidities, resistance

- **2016 national drug report:**
 - **20 937** high risk opioid users
 - **1 480** of which receive opioid substitution
- **2017 national HIV data:**
 - 15.31% of IDUs were infected with HIV
 - Most are men (85%) aged 20-40 years old (60%)
 - Around half (49%) use heroin in various combinations
 - **60%** were late presenters
 - 44% were diagnosed with advanced HIV/AIDS
- Most IDUs are co-infected with HCV (**83.33%** of cases diagnosed in 2017)
- Phylogenetic analysis on a smaller group of 117 IDUs showed the following:
 - HCV infection occurs before HIV in 80.3% of cases
 - simultaneous HIV and HCV transmission is less frequent (19.65%)
- No national data on adherence in IDUs but it is presumed to be low, hence only anecdotal cases of DAA treatment are available in this patient group

Reaching the 90-90-90 UNAIDS targets

Cascade of HIV care - Romania 31 December 2017



- Increased HIV testing, diagnosis and ART coverage

- High frequency of HIV-1 **F1 subtype (>80%)**
- Other subtypes: C and B in MSMs, G and B in IDUs

- Most ARV drugs are universally available in Romania recommended irrespective of CD4 T cell count since 2011
- Low transmitted drug resistance (14.75%)
- Small individual studies hinted at a potentially higher rate of major mutations in treatment-naïve patients
- In a study on 350 patients with multiple ART regimens around half displayed major NRTI mutations

Bibliography

- Hersh et al. Lancet 1991
- WHO Report Weekly Epidemiol Rec 1991
- Mbisa et al. AIDS Res Human Retrovir, 2012
- Romanian National Committee for Fighting Against AIDS. HIV/AIDS - update 31 December 2017. http://cnlas.ro/images/doc/31122017_rom.pdf
- C. Oprea, WAVE Workshop , 15th European AIDS Conference, 2015, Barcelona, Spain
- EMCDDA - Romania Country Report 2018 http://www.emcdda.europa.eu/countries/drug-reports/2018/romania_en
- Paraschiv S, [Epidemic dispersion of HIV and HCV in a population of co-infected Romanian injecting drug users, 2017](#)